Literature DB >> 32895251

Rheumatoid arthritis in a patient with cystic fibrosis: challenging treatment options.

Kelly Lynn Delaney-Nelson1, Sheena Marie Henry2, Chokkalingam Siva2.   

Abstract

A 26-year-old Caucasian male patient with a history of cystic fibrosis presented with a 6-month history of diffuse joint pain and swelling. He was found to have active synovitis in bilateral wrists and proximal interphalangeal joints of the hands on physical examination. He was diagnosed with seropositive rheumatoid arthritis since he had positive anti-cyclic citrullinated peptide antibodies and erosions on hand and foot X-rays. The patient has responded well to abatacept which may have less infection risk compared with other biological therapies. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biological agents; cystic fibrosis; rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32895251      PMCID: PMC7476469          DOI: 10.1136/bcr-2020-234305

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Safe and effective tumour necrosis factor-α inhibitor (etanercept) treatment of chronic episodic arthritis in a patient with cystic fibrosis.

Authors:  T Adelsten; N Rasmussen; T L Katzenstein; C T Nielsen
Journal:  Scand J Rheumatol       Date:  2016-01-20       Impact factor: 3.641

2.  Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.

Authors:  Huifeng Yun; Fenglong Xie; Elizabeth Delzell; Emily B Levitan; Lang Chen; James D Lewis; Kenneth G Saag; Timothy Beukelman; Kevin L Winthrop; John W Baddley; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

3.  Cystic fibrosis and rheumatoid arthritis.

Authors:  P V Gardiner; S D Roberts; A L Bell
Journal:  Br J Rheumatol       Date:  1989-04

4.  Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.

Authors:  Michael D George; Joshua F Baker; Kevin Winthrop; Evo Alemao; Lang Chen; Sean Connolly; Jesse Y Hsu; Teresa A Simon; Qufei Wu; Fenglong Xie; Shuo Yang; Jeffrey R Curtis
Journal:  Ann Intern Med       Date:  2019-05-21       Impact factor: 25.391

5.  Seropositive rheumatoid arthritis in a patient with cystic fibrosis.

Authors:  D M Sagransky; R A Greenwald; J D Gorvoy
Journal:  Am J Dis Child       Date:  1980-03

6.  Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.

Authors:  François Montastruc; Christel Renoux; Marie Hudson; Sophie Dell'Aniello; Teresa A Simon; Samy Suissa
Journal:  Semin Arthritis Rheum       Date:  2019-01-25       Impact factor: 5.532

Review 7.  Musculoskeletal manifestations in cystic fibrosis.

Authors:  Estelle Botton; Alain Saraux; Hermine Laselve; Sandrine Jousse; Paul Le Goff
Journal:  Joint Bone Spine       Date:  2003-09       Impact factor: 4.929

8.  Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy.

Authors:  G Fitch; K Williams; J E Freeston; S Dass; A Grainger; R Hodgson; L Horton; P Whitaker; D Peckham
Journal:  J Cyst Fibros       Date:  2016-01-20       Impact factor: 5.482

9.  Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha.

Authors:  Brian Casserly; Walter Donat
Journal:  Lung       Date:  2009-02-27       Impact factor: 2.584

10.  Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.

Authors:  Gulsen Ozen; Sofia Pedro; Rebecca Schumacher; Teresa A Simon; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2019-06-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.